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(1952–2013)Tony PawsonTony Pawson, aworld-renowned scientist
and a pioneer who made groundbreaking
contributions that shaped our current un-
derstanding of how cellular signal trans-
duction pathways are regulated in normal
tissues and in cancer cells, sadly passed
away on August 7, 2013 at the age of 60.
Anthony James Pawson was born on
October 18, 1952 in Maidstone in the
County of Kent in England. His mother
was a high school biology teacher with a
special interest in botany. His father was
a well-known soccer player who played
for the Oxford University team and for
the English soccer team at the 1952
Olympiad in Helsinki. His father was also
a successful cricket player, a member of
the English fly-fishing team for the 1989
world championship, and, later in life,
an author and correspondent for the
Observer. Tony mentioned that he
obtained his interest in science and the
natural world from his mother, but his
passion for writing, his competitiveness,
his determination, and his own love of fly
fishing from his father.
After spending his school years at
Winchester College, Tony received his
undergraduate education as a member
of Clare College at Cambridge University.
In Cambridge, he became interested in
biochemistry and had the opportunity to
spend time in the laboratory performing
experiments in the field of protein synthe-
sis. In 1973, Tonymoved to London for his
Ph.D. degree at ICRF (Imperial Cancer
Research Fund, which is now called
Cancer Research UK) with Alan Smith.
During Tony’s Ph.D. studies, the focus of
his research was the mode of action and
mechanism of oncogenesis mediated
by retroviruses and how retroviruses
propagate themselves. After obtaining
his Ph.D. in 1976, Tony crossed the
Atlantic and worked at the laboratory of
Steven Martin at the University of Califor-
nia, Berkeley. Martin focused on investi-
gating the mechanism of action of Rous
Sarcoma virus, a retrovirus that causes
tumors in chickens and transforms
cultured cells by expressing its oncogenic
protein, v-Src. During his postdoctoral
training, Tony started to explore the struc-Reprinted from Cell 154, Published onlineture and mechanism of action of the
Fujinami avian sarcoma virus and the
role played by its oncogenic protein,
v-Fps, in cell transformation. In 1981,
Tony took an independent faculty position
at the University of British Columbia in
Vancouver, where he continued to inves-
tigate the oncogenic v-Fps protein,
increasingly focused on the role of its tyro-
sine kinase activity in cell transformation.
A few years later, in 1985, Tony moved
to the Samuel Lunenfeld Research Insti-
tute at Toronto’s Mount Sinai Hospital,
where he became Distinguished Investi-
gator and Director of Research, and was
also Professor of Molecular Genetics at
the University of Toronto. Tony remained
in Toronto for the rest of his career.
Tony was very much at the center of
an exceptional convergence of several
different areas of basic biomedical
research during the last three decades
of the 20th century, which revolutionized
our understanding of the molecular basis
of cell signaling and malignant transfor-
mation. These important discoveries
contributed to new approaches for the
development of many new cancer drugs.September 5, 2013. http://dx.doi.org/10.1016/The molecular basis of cancer was re-
vealed through a stunning explosion of
discoveries. These advances include:
the genetic origins of malignancies; the
mode of action of retroviral oncogenes;
the discoveries of new growth factors
and cytokines that stimulate cell prolifera-
tion, differentiation, and other vital cellular
processes; the methodology to identify
and track genetic changes in cancer
cells; the identification of evolutionary
conserved critical components of cellular
signaling pathways in nematodes and
Drosophila; and biochemical determina-
tion of how signals that are initiated at
the cell surface and are propagated intra-
cellularly by growth factor receptor acti-
vation stimulate cell proliferation and
other basic processes that are required
for cellular homeostasis. Subsequent
application of this new knowledge led to
the development of what is now defined
as cancer-targeted therapies, which
have changed the way in which many
deadly cancers are now being treated.
Tony is perhapsbest known for his iden-
tification of the Src homology 2, or SH2,
domain and the resulting concept of
modular interaction domains as key
elements of the molecular infrastructure
of signaling. While inspecting the primary
structure of v-Fps early in his career,
Tony and his colleagues made an impor-
tant observation. They realized that, in
addition to the catalytic tyrosine kinase
domain of v-Fps that is also seen in the
oncogenic Src and Abl tyrosine kinases,
these oncogenic proteins contain a
conserved noncatalytic region of 100
amino acids, which they termed the SH2
domain (the tyrosine kinase is the SH1
domain). Through biochemical analyses
of the tyrosine kinase activities of a variety
of v-Fps mutants and comparison of their
cellular transformation properties, Tony’s
laboratory demonstrated that the v-Fps
SH2 domain plays an important role in
controlling both the tyrosine kinase activ-
ity and cell transformation. Members of
the Src and Abl tyrosine kinase families
contain an additional conserved noncata-
lytic region of 60 amino acids, desig-
nated the Src homology 3 (SH3) domain,j.cell.2013.08.038. ª2013 Elsevier Inc. 273
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Src and Abl. Tony proposed that SH2
and SH3 domains function as indepen-
dent protein modules that maintain their
unique functions in different host proteins
and that they play important regulatory
roles in controlling the activity and locali-
zation of Src and other cytoplasmic tyro-
sine kinases. This concept of modularity
gained significant traction when the labo-
ratory of Hidesaburo Hanafusa found
that the transforming gene of the CT10
retrovirus, v-Crk, encodes a viral gag pro-
tein fused to only SH2 and SH3 domains,
demonstrating that SH2 andSH3domains
can function alone as oncogenes. The
SH2 domain of Crk was shown to bind
directly to phosphotyrosine (P-Tyr)-
containing proteins, indicating that SH2
domains may recognize specific tyro-
sine-containing regions in a phosphoryla-
tion-dependent manner. Because many
signaling molecules with different enzy-
matic activities, such as phospholipase
Cg (PLCg), RasGTPase-activating protein
(GAP), and the Src family kinases, contain
SH2 domains, this realization provided a
link between activation of cytoplasmic
and receptor tyrosine kinases (RTKs).
Indeed, experiments performed in Tony’s
and other laboratories demonstrated
that, following their stimulation with
ligands, the EGF receptor (EGFR), PDGF
receptor (PDGFR), and other activated
RTKs form physical complexes with
signaling molecules such as PLCg, GAP,
or adaptor proteins such as Grb2 or Nck
by binding to the SH2 domains of these
signaling proteins. For example, in 1992,274 Reprinted from Cell 154, Published onlineTony’s laboratory demonstrated that
complex formation between the scaffold
protein Shc and phosphotyrosines on
activated EGFR leads to tyrosine phos-
phorylation of Shc, which in turn forms a
complex with the SH2 domain of the
adaptor protein Grb2. Grb2 uses its two
SH3 domains to bind the guanine nucleo-
tide exchange factor Sos so that Shc
effectively recruits Sos to the cell mem-
brane (and thus activates Ras) through
SH2 and SH3 domain-mediated interac-
tions. The resulting activated (GTP-bound)
Ras molecules stimulate a cascade of
three protein kinases, resulting in activa-
tion and nuclear translocation of MAP
kinase. This highly conserved signaling
pathway relays information from the cell
membrane to the nucleus and other intra-
cellular compartments to regulate a vari-
ety of EGF-induced cellular processes.
More than 20 years later, in one of his
last and most elegant articles that was
published in July 2013—only three weeks
before he passed away—Tony’s labora-
tory described a comprehensive analysis
of the cellular functions of Shc at different
time points following EGF stimulation. His
laboratory used mass spectrometry and
other state-of-the-art technologies to
demonstrate that Shc responds to EGF
stimulation in ‘‘multiple waves of distinct
phosphorylation events and protein inter-
actions.’’ In other words, at different time
points following EGF stimulation, Shc
forms distinct complexes with different
positive or negative regulators to control
many of the pleiotropic cellular responses
induced by EGF stimulation. These twoSeptember 5, 2013. http://dx.doi.org/10.1016/publications, spanning more than two
decades of scientific effort, provide a
clear testament to the originality,
brilliance, and focus that have been a
hallmark of Tony’s entire scientific career.
In addition to his main interest in eluci-
dating the biological roles and mecha-
nisms underlying the actions of SH2,
SH3, and other small protein modules in
mediating protein-protein and other inter-
actions during signal transduction, Tony’s
laboratory made important contributions
to other fields of biomedical research,
including analysis of molecular mecha-
nisms that govern cellular polarity and
molecular mechanisms that control axon
guidance, as well as systems biology
with an emphasis on elucidation of the
dynamic nature of molecular events
during cellular signaling. In all of these
studies, he showed an uncanny ability to
marry advances in technology with the
most important biological questions to
view the entire cell in terms of its molecu-
lar infrastructure.
The death of Tony Pawson shocked
and saddened his many colleagues,
former students, postdoctoral fellows,
and friends all over the world. We will
miss Tony’s thoughtful and eloquent
lectures. We will miss Tony’s inspiring
publications and the elegance and clarity
of his scientific mind. We will miss our
informal discussions at scientific meet-
ings that were filled with good humor,
Tony’s characteristic chuckle, and his
sharp insights. Tony’s legacy will be
remembered and will be an inspiration
for future generations of scientists.
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